Cannabis Report
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator: ahab333
Search This Board: 
Last Post: 9/21/2018 12:59:44 PM - Followers: 72 - Board type: Free - Posts Today: 4


BioTime, Inc.  (BTX)





Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389






BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us


The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:









Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at:





Recent News:








Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038


Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

Phone:  510.521.3390 ext 301






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX News: BioTime Warrants to Expire on October 1, 2018 07:00 AM
BTX News: BioTime met à jour le calendrier de distribution des actions AgeX à ses actionnaires 09/18/2018 11:52:00 AM
BTX News: BioTime aktualisiert Zeitplan für die Verteilung der AgeX-Aktien an BioTime-Aktionäre 09/18/2018 11:51:00 AM
BTX News: Current Report Filing (8-k) 09/18/2018 07:06:28 AM
BTX News: BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer 09/18/2018 07:00:00 AM
News News Alert: BioTime Warrants to Expire on October 1, 2018 09/21/2018 07:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1100   I Don't Think the Warrants Matter bobby2loaves 09/21/18 12:59:44 PM
#1099   I called and talked with BTX investor relations madprophet 09/21/18 11:49:57 AM
#1098   Hmmmmmmmmmmmmm, a warning for warrant expiration! Wonder if ahab333 09/21/18 11:20:49 AM
#1097   Oncocyte has posted a recent corporate presentation. pymadams 09/21/18 11:07:28 AM
#1096   Very kind of you to take the time, Jobur77 09/20/18 09:23:01 AM
#1095   Jobu77: The "Record Date" that Biotime is bobby2loaves 09/20/18 07:15:59 AM
#1094   So buying now might include one in the Jobur77 09/19/18 05:03:43 PM
#1093   I have only been following BTX for about bobby2loaves 09/18/18 08:21:21 AM
#1092   Board kick out West, Adi kicked after failing DeepDive 09/18/18 07:13:02 AM
#1091   I received this information on AgeX share distribution ahab333 09/17/18 10:34:21 AM
#1090   Every press release on AgeX transition seems to Cincinnatus 09/06/18 12:24:20 PM
#1089   Sounds plausible 2loaves and I think you may ahab333 09/06/18 12:03:06 PM
#1088   While BTX will indeed only retain 3mm shares bobby2loaves 09/05/18 07:56:44 PM
#1087   Cincy, BTX now holds only 41% of AgeX ahab333 09/05/18 06:48:33 PM
#1086   " BioTime will continue to own a meaningful Cincinnatus 09/05/18 06:21:38 PM
#1085   Agex Sale of sharesto Juvenescence ahab333 09/05/18 02:12:29 PM
#1084   I looked into whether the military might be terry hallinan 08/21/18 01:30:12 PM
#1083   BTX Osteoarthritis Solution at Military Medical Conference bobby2loaves 08/20/18 07:29:54 PM
#1082   ahab333, Very interesting. This is something I found terry hallinan 08/17/18 04:48:23 PM
#1081   I know about Asprin and mortrin. I ahab333 08/17/18 01:54:20 PM
#1080   Ahab, It was just particularly personal for me. terry hallinan 08/17/18 01:22:53 PM
#1079   Yes Terry, I saw that one too but ahab333 08/17/18 10:55:21 AM
#1078   Ahab, This is a separate release picked up by terry hallinan 08/16/18 12:54:50 PM
#1077   AgeX announces acquisition of certain patents from Escape ahab333 08/16/18 09:44:19 AM
#1076 mick 08/11/18 03:04:40 PM
#1075   Ovshinsky went to my high school terry hallinan 08/10/18 07:57:03 AM
#1074   Ovshinsky went to my high school CaptainOblivious 08/09/18 08:04:06 PM
#1073   What I think the difference is... madprophet 08/09/18 02:33:14 PM
#1072   Anyone have an idea why this time it terry hallinan 08/09/18 05:28:54 AM
#1070   In terms of sheer dollars, BTX is coming bobby2loaves 08/08/18 08:36:36 PM
#1069   Just wondering. Juvenescence paid about $3 a Cincinnatus 08/08/18 06:00:51 PM
#1068   I agree that your math and their assets Cincinnatus 08/05/18 07:15:13 PM
#1067   an especially unlikely situation for a developmental biotech.[/ terry hallinan 08/05/18 06:46:12 PM
#1066   Book Value of BTX Getting Compelling bobby2loaves 08/05/18 10:48:43 AM
#1065   Cincinnatus, Thank you. I will look into this terry hallinan 08/05/18 01:12:13 AM
#1064   "I know nothing at all about Jim Mellon Cincinnatus 08/04/18 06:29:06 PM
#1063   Cincinnatus, Since Juvenescence is going to be running the terry hallinan 08/04/18 04:10:05 PM
#1062   OK, let's take it out of the MBA Cincinnatus 08/04/18 10:32:01 AM
#1061   DeepDive, I believe West is less important for Btx’s terry hallinan 08/04/18 01:48:59 AM
#1060   Simple. West is an R&D guy. Been all his DeepDive 08/04/18 12:47:41 AM
#1059   OK, BTX has less than 5% of AgeX Cincinnatus 08/03/18 03:15:00 PM
#1058   Talked with the Investor relations go for BTX madprophet 08/03/18 01:30:57 PM
#1057   Was I reading the PR right. madprophet 08/03/18 11:28:26 AM
#1056   After the spinoff, BTX is going to be bobby2loaves 08/03/18 08:21:13 AM
#1055   Selections from 2ndQ report: terry hallinan 08/03/18 04:31:42 AM
#1054   Cincinnatus, If Premvia has a 510K CLEARANCE, how long terry hallinan 08/02/18 04:05:11 PM
#1053   AgeX Share Breakdown bobby2loaves 08/02/18 01:12:56 PM
#1052   So now Juvenescence owns more shares in AgeX Cincinnatus 08/02/18 01:05:04 PM
#1051   If Premvia has a 510K CLEARANCE, how long Cincinnatus 08/02/18 01:01:17 PM
#1050   More shenanigans??? Cincinnatus 08/02/18 10:22:37 AM